Revenue
2016
2017
2018
2019
2020
2021
2022
2023
Oruka Therapeutics, Inc. (ORKA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — |
| Research & development | $100.6M | $75.1M | $1.0M | $4.7M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M | $7.1M | $5.6M | $2.9M | $1.1M | $2.3M | $3.1M | — | — | — | — | — | — |
| Operating expenses | $122.1M | $88.1M | $7.3M | $10.6M | $19.3M | $9.8M | $5.8M | $8.1M | $18.7M | $16.6M | $11.5M | $9.7M | $6.9M | $4.3M | $7.4M | $9.2M | — | — | — | — | — | — |
| Operating income | −$122.1M | −$88.1M | −$7.3M | −$10.6M | −$19.3M | −$9.8M | −$5.8M | −$8.1M | −$18.7M | −$16.6M | −$11.5M | −$9.7M | −$6.9M | −$4.3M | −$7.4M | −$9.2M | — | — | — | — | — | — |
| EBITDAderived | — | — | −$7.3M | −$10.6M | −$19.3M | −$9.8M | −$5.8M | −$8.1M | −$18.7M | −$16.6M | −$11.4M | −$9.7M | −$6.9M | −$4.3M | −$6.8M | −$8.8M | — | — | — | — | — | — |
| Net income | −$105.4M | −$83.7M | −$5.3M | −$9.9M | −$19.3M | −$9.7M | −$5.5M | −$7.9M | −$18.5M | −$16.4M | −$11.4M | −$9.7M | −$6.9M | −$4.3M | −$5.4M | −$8.4M | −$9.1M | −$19.4M | −$14.0M | −$5.2M | −$1.5M | −$511,000 |
| Basic EPSper diluted share | — | -$3.87 | -$0.37 | -$0.69 | -$1.39 | -$2.07 | -$4.15 | -$10.31 | -$1.77 | -$1.81 | -$1.82 | -$3.31 | -$1.04 | -$1.94 | -$3.21 | -$0.99 | — | — | — | — | — | — |
| Diluted EPSper diluted share | — | -$3.87 | -$0.37 | -$0.69 | -$1.39 | -$2.07 | -$4.15 | -$10.31 | -$1.77 | -$1.81 | -$1.82 | -$3.31 | -$1.04 | -$1.94 | -$3.21 | -$0.99 | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Agarwal ArjunSenior Vice President, Finance | SellCommon Stock | 699 | $82.15 | $57.4K | 15.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Agarwal ArjunSenior Vice President, Finance | SellCommon Stock | 888 | $80.01 | $71.0K | 16.0K |
| Jun 15, 2026Form 4 · 10b5-1 | Agarwal ArjunSenior Vice President, Finance | SellCommon Stock | 395 | $69.69 | $27.5K | 16.9K |
| Jun 15, 2026Form 4 · 10b5-1 | Goncalves JoanaChief Medical Officer | SellCommon Stock | 947 | $69.69 | $66.0K | 32.7K |
| Jun 15, 2026Form 4 · 10b5-1 | Goncalves JoanaChief Medical Officer | SellCommon Stock | 300 | $70.62 | $21.2K | 33.7K |